Siemens Healthineers AG
XTRA-SHL
Company Overview
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Name
Siemens Healthineers AG
CEO
Dr. Bernhard Montag
Website
www.siemens-healthineers.com
Sector
Health Care Equipment and Supplies
Year Founded
-
Profile
Market Cap
€55.56B
EV
€70.41B
Shares Out
1,115.79M
Revenue
€22.09B
Employees
71,800
Margins
Gross
37.81%
EBITDA
15.77%
Operating
12.32%
Pre-Tax
11.1%
Net
8.43%
FCF
6.61%
Returns (5Yr Avg)
ROA
5.08%
ROTA
18.33%
ROE
12.19%
ROCE
9.88%
ROIC
5.91%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
€59.36
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
€2,056M
Net Debt
€14.8B
Debt/Equity
0.92
EBIT/Interest
6.24
Growth (CAGR)
Rev 3Yr
9.75%
Rev 5Yr
9.43%
Rev 10Yr
—
Dil EPS 3Yr
1.76%
Dil EPS 5Yr
3.07%
Dil EPS 10Yr
—
Rev Fwd 2Yr
5.11%
EBITDA Fwd 2Yr
18.83%
EPS Fwd 2Yr
13.75%
EPS LT Growth Est
12.47%
Dividends
Yield
—
Payout
56.97%
DPS
€0.95
DPS Growth 3Yr
5.9%
DPS Growth 5Yr
6.3%
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
11.83%